Klencke Barbara
- SEC CIK
- 0001647647
No open-market purchases or sales filed in the past year.
Current role at each company
- XNCR Xencor IncDirectoras of Jul 8, 2026
- TCRX TScan Therapeutics, Inc.Directoras of May 22, 2026
- ALXO Alx Oncology Holdings IncChief Medical Officeras of Apr 17, 2026
- EFTR eFFECTOR Therapeutics, Inc.Directoras of Jun 13, 2024
- SRRA Sierra Oncology, Inc.Chief Medical Officeras of Jul 1, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Klencke Barbara as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
TCRX TScan Therapeutics, Inc.
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2024 (view filing) | Sep 23 | 1 day | Klencke BarbaraDirector | PPurchaseVoting Common Stock | +5.00K | $5.29 | +$26.4K | +12.5%45.0K after | |
| Aug 27, 2024 (view filing) | Aug 23-26 | 4 days | Klencke BarbaraDirector | PPurchaseVoting Common Stock | +10.0K | $5.61 | +$56.1K | +33.3%40.0K after | 2 lots |
| Dec 18, 2023 (view filing) | Dec 14 | 4 days | Klencke BarbaraDirector | PPurchaseVoting Common Stock | +5.00K | $5.08 | +$25.4K | +20.0%30.0K after |